Loading...
Cellectis S.A.
CLLS•NASDAQ
Healthcare
Biotechnology
$3.05
$1.05(52.50%)
Cellectis S.A. (CLLS) Financial Performance & Income Statement Overview
Review Cellectis S.A.’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
5397.48%
↑ 5397.48%
Operating Income Growth
38.79%
↑ 38.79%
Net Income Growth
63.62%
↑ 63.62%
Operating Cash Flow Growth
192.90%
↑ 192.90%
Operating Margin
-129.41%
↓ 129.41%
Gross Margin
63.70%
↑ 63.70%
Net Profit Margin
-127.08%
↓ 127.08%
ROE
-46.10%
↓ 46.10%
ROIC
-30.59%
↓ 30.59%
Cellectis S.A. (CLLS) Income Statement & Financial Overview
Review Cellectis S.A.'s (CLLS) income statement with detailed quarterly and annual figures.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $12.72M | $16.20M | $8.06M | $4.53M |
| Cost of Revenue | $0.00 | $0.00 | -$1.44M | $0.00 |
| Gross Profit | $12.72M | $16.20M | $9.50M | $4.53M |
| Gross Profit Ratio | $1.00 | $1.00 | $1.18 | $1.00 |
| R&D Expenses | $20.87M | $23.83M | $23.52M | $22.32M |
| SG&A Expenses | $3.45M | $5.17M | $3.88M | $5.10M |
| Operating Expenses | $23.40M | $26.97M | $25.27M | $25.42M |
| Total Costs & Expenses | $23.40M | $26.97M | $25.27M | $25.42M |
| Interest Income | $3.57M | $3.02M | $2.77M | $1.92M |
| Interest Expense | $1.91M | $1.92M | $1.83M | $1.79M |
| Depreciation & Amortization | $5.83M | $4.72M | $4.73M | $4.57M |
| EBITDA | $14.17M | -$16.48M | -$18.90M | -$14.41M |
| EBITDA Ratio | $1.11 | -$1.02 | -$2.34 | -$3.18 |
| Operating Income | -$10.68M | -$10.77M | -$17.21M | -$21.29M |
| Operating Income Ratio | -$0.84 | -$0.66 | -$2.14 | -$4.70 |
| Other Income/Expenses (Net) | $17.12M | -$12.35M | -$8.25M | $26.67M |
| Income Before Tax | $6.44M | -$23.12M | -$25.46M | $5.38M |
| Income Before Tax Ratio | $0.51 | -$1.43 | -$3.16 | $1.19 |
| Income Tax Expense | $514000.00 | -$59000.00 | -$193000.00 | -$262000.00 |
| Net Income | $5.92M | -$23.06M | -$25.27M | $5.64M |
| Net Income Ratio | $0.47 | -$1.42 | -$3.13 | $1.25 |
| EPS | $0.07 | -$0.26 | -$0.28 | $0.08 |
| Diluted EPS | $0.07 | -$0.26 | -$0.28 | $0.05 |
| Weighted Avg Shares Outstanding | $89.85M | $89.85M | $89.85M | $71.81M |
| Weighted Avg Shares Outstanding (Diluted) | $89.85M | $89.85M | $89.85M | $103.09M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan